Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone.

Eighteen consecutive patients with measurable locally advanced or metastatic pancreatic adenocarcinoma were treated with goserelin (Zoladex) 3.6 mg subcutaneously every 4 weeks. Hydrocortisone 20 milligrams twice daily was commenced with the second injection of goserelin. Objective tumour response w...

Descripción completa

Detalles Bibliográficos
Autores principales: Philip, P. A., Carmichael, J., Tonkin, K., Buamah, P. K., Britton, J., Dowsett, M., Harris, A. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968191/
https://www.ncbi.nlm.nih.gov/pubmed/8431370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968191/
https://www.ncbi.nlm.nih.gov/pubmed/8431370

Ejemplares similares